Researcher’s Profile

Justine Kahn, MD

Body: 

Dr. Justine Kahn is a Pediatric Oncologist and a clinical investigator specializing in survival outcomes, cancer care delivery, and health equity in children and adolescent/young adults (AYA) with Hodgkin lymphoma, non-Hodgkin lymphoma and acute lymphoblastic leukemia (ALL). 

Dr. Kahn received her MD from the Icahn School of Medicine at Mount Sinai in New York and completed her Pediatric Residency at Mount Sinai Kravis Children’s Hospital in New York. Dr. Kahn completed her Clinical Fellowship in Pediatric Hematology/Oncology at Columbia University Medical Center. While in residency, Dr. Kahn was elected to Alpha Omega Alpha, the national medical honor society which recognizes high educational achievement. During her fellowship, Dr. Kahn served as a Postdoctoral Research Fellow in Cancer-Related Population Sciences supported by the National Cancer Institute for her work in cancer care delivery, health equity, and health outcomes research. Upon graduation from fellowship, Dr. Kahn joined the Pediatric Hematology/Oncology Division at Columbia University Medical Center as an Oncology Instructor and Attending Physician. She is currently involved in patient care, clinical trials research, and health outcomes research. In June of 2018, Dr. Kahn obtained a Master of Science in Patient Oriented Research at the Columbia Mailman School of Public Health. 

Dr. Kahn is actively conducting research through studies developed in the Dana-Farber Cancer Institute (DFCI) ALL Consortium, the Children's Oncology Group (COG), and at Columbia University. Columbia boasts a strong commitment to health disparities research in one of the most diverse patient populations in the United States. Dr. Kahn has chosen to focus her research efforts on underserved populations because studies suggest that poor access-to-care, low health literacy, and financial stress can all negatively impact survival in children and AYAs with cancer.  

Dr. Kahn is supported in part by the Lymphoma Research Foundation and recently received an institutional Career Development Award for her ongoing work on survival disparities in children and AYAs with Hodgkin lymphoma.  She serves as CUMC site Principal Investigator for the DFCI ALL Consortium. 

Quote: 

"Where systematic differences in health are judged to be avoidable by reasonable action, they are, quite simply, unfair. It is this that we label health inequity. Putting right these inequities – the huge and remediable differences in health within and between countries – is a matter of social justice, and reducing health inequities is an ethical imperative."

The World Health Organization Commission on Social Determinants of Health, 2005

Research Statement: 

Dr. Kahn is actively conducting research through studies developed in the Dana-Farber Cancer Institute (DFCI) ALL Consortium, the Children's Oncology Group (COG), and at Columbia University. Columbia boasts a strong commitment to health disparities research in one of the most diverse patient populations in the United States. Dr. Kahn has chosen to focus her research efforts on underserved populations because studies suggest that poor access-to-care, low health literacy, and financial stress can all negatively impact survival in children and AYAs with cancer.  

Dr. Kahn is supported in part by the Lymphoma Research Foundation and recently received an institutional Career Development Award for her ongoing work on survival disparities in children and AYAs with Hodgkin lymphoma.  She serves as CUMC site Principal Investigator for the DFCI ALL Consortium. 

Publications: 

Kahn JM*, Kelly KM. Adolescent and young adult Hodgkin lymphoma: Raising the bar through collaborativescienceandmultidisciplinarycare.PediatricBlood&Cancer.2018Mar30:e27033.doi: 10.1002/pbc.27033. [Epub ahead of print] Review. PubMed PMID:29603618

Kahn JM*, Cole PD, Blonquist TM, Stevenson K, Jin Z, Barrera S, Davila R, Roberts E, Neuberg DS, Athale UH, Clavell LA, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJG, Sallan SE, Silverman LB, Kelly KM. An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001. Pediatric Blood & Cancer. 2018 Mar;65(3). doi:10.1002/pbc.26871.PubMedPMID:29090520; PubMed Central PMCID: PMC5766393.       

Kahn JM*,Ozuah NW, Dunleavy K, Henderson TO, Kelly K, LaCasce A. Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes. Blood Advances.2017Oct10;1(22):1945-1958.doi:10.1182/bloodadvances.2017008748.PubMedPMID: 29296842; PubMed Central PMCID: PMC5728148.

Rustia E, Violago L, Jin Z, Foca MD, Kahn JM, Arnold S, Sosna J,Bhatia M, Kung AL,George D, Garvin JH, Satwani P. Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood & Marrow Transplantation.2016 Sep;22(9):1646-1653. doi: 10.1016/j.bbmt.2016.05.014. Epub 2016 May 29. PubMed PMID: 27252110; PubMed Central PMCID: PMC5496767

Kahn JM*, Athale UH, Clavell LA, Cole PD, Leclerc JM, Laverdiere C, Michon B, Schorin MA,Welch JJ, Sallan SE, Silverman LB, Kelly KM. How Variable Is Our Delivery of Information? Approaches to Patient Education About Oral Chemotherapy in the Pediatric Oncology Clinic. Journal of Pediatric Health Care. 2017 Jan - Feb;31(1): e1-e6. doi: 10.1016/j.pedhc.2016.06.004. PubMed PMID: 27461368; PubMed Central PMCID: PMC5154954

Kahn JM*,KeeganTH,TaoL,AbrahãoR,BleyerA,VinyAD.Racialdisparitiesinthesurvivalof American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma. Cancer. 2016 Sep 1;122(17):2723-30. doi: 10.1002/cncr.30089. PubMed PMID: 27286322; PubMed Central PMCID:PMC4992431

Kolb M, Offer K, Jin Z, Kahn J, Bhatia M, Kung AL, Garvin JH, George D, Satwani P. Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood & Marrow Transplantation. 2016 May;22(5):957-61. doi: 10.1016/j.bbmt.2016.02.005. PubMed PMID: 26880117; PubMed Central PMCID:PMC5496769

Al Mulla N, Kahn JM*, Jin Z, Qureshi M, Karamehmet E, Yoon-Jeong Kim G, Levinson AL, Bhatia M, GarvinJ H, George D, Kung AL, SatwaniP.SurvivalImpactofEarlyPost-Transplant Toxicitiesin Pediatric and Adolescent Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Malignant and Non-Malignant Diseases: Recognizing Risks and Optimizing Outcomes.Biology of Blood & Marrow Transplantation. 2016 Aug;22(8):1525-1530. doi: 10.1016/j.bbmt.2016.05.012. PubMed PMID: 27223110; PubMed Central PMCID:PMC5496771

Satwani P, Kahn J, Jin Z. Making strides and meeting challenges in pediatric allogeneic hematopoietic cell transplantation clinical trials in the United States: Past, present and future.Contemporary Clinical Trials. 2015 Nov;45(Pt A):84-92

Kahn JM*,Hamburger-Smilow, E,Bhatia, M.Hematopoietic cell transplantation and sickle cell disease: An option for everyone? Current Pediatrics Reports. 2015 June;3(2):146-153